Editas Medicine Outperforms Medical Sector This Year Despite Zacks Rank #2

Editas Medicine (EDIT) has outperformed the Medical sector in 2023, gaining 98.4% year-to-date compared to the sector's average return of -5.4%. The company has a Zacks Rank of #2 (Buy) and a Zacks Consensus Estimate for full-year earnings that has moved 0.4% higher within the past quarter. Adherex Technologies Inc. (FENC) has also outperformed the sector, gaining 33.1% year-to-date and having a Zacks Rank of #2 (Buy).

July 02, 2025

Editas Medicine (EDIT) and Adherex Technologies Inc. (FENC) have both demonstrated strong performance in the Medical sector during 2023. Editas Medicine, a member of the Medical sector, has gained 98.4% year-to-date (YTD), significantly outperforming the sector's average return of -5.4%. This impressive performance is reflected in the company's Zacks Rank of #2 (Buy) and a Zacks Consensus Estimate for full-year earnings that has moved 0.4% higher within the past quarter [1].

Similarly, Adherex Technologies Inc. (FENC) has also shown robust performance, gaining 33.1% YTD. The stock's Zacks Rank is also #2 (Buy), indicating a strong buy signal. The consensus estimate for Adherex Technologies Inc.'s current year EPS has increased by 360% over the past three months, highlighting the growing optimism among analysts [1].

Both companies belong to the Medical - Biomedical and Genetics industry, which has gained an average of 1.5% YTD. This industry rank is #147 in the Zacks Industry Rank, indicating that Editas Medicine and Adherex Technologies Inc. are performing better than average within their industry group [1].

The strong performance of these stocks can be attributed to their focus on innovation and R&D, as highlighted by their Zacks Rank and the positive changes in their earnings estimates. The alignment of executive compensation with long-term innovation milestones and financial performance is a strategic imperative in the healthcare sector [2]. Companies like Editas Medicine and Adherex Technologies Inc. that prioritize innovation and R&D are better positioned to deliver robust shareholder returns while advancing medical breakthroughs.

Investors interested in the Medical sector should continue to track Editas Medicine and Adherex Technologies Inc. for potential future gains. These stocks have shown a strong ability to outperform their sector and industry peers, making them attractive investment opportunities.

References:
[1] https://www.nasdaq.com/articles/are-medical-stocks-lagging-editas-medicine-edit-year
[2] https://www.ainvest.com/news/aligning-executive-pay-innovation-healthcare-sector-path-long-term-2507/